Related Experiment Video
Updated: Jun 6, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Botulinum toxin A: is it really that fragile a molecule?
Debraj Shome1, Akshay G Nair, Rinky Kapoor
1Department of Facial Plastic Surgery, Apollo Hospitals, Hyderabad, India. debraj_shome@yahoo.com
Botulinum toxin type A remains effective even after vigorous agitation for up to six weeks. This study demonstrates the molecule's stability, challenging previous assumptions about its fragility.
Area of Science:
- Biochemistry
- Pharmacology
- Neuroscience
Background:
- Botulinum toxin A is widely considered a fragile molecule.
- Current recommendations advise using reconstituted formulations within 4 hours due to perceived instability.
- Agitation of the vial is strongly discouraged.
Purpose of the Study:
- To investigate the stability and efficacy of reconstituted onabotulinumtoxinA (BoNT-A) when subjected to vigorous agitation.
- To challenge the established protocols regarding the handling of reconstituted BoNT-A.
Main Methods:
- An experimental animal study using 64 mice.
- Reconstituted onabotulinumtoxinA was vigorously agitated using a mechanized apparatus for up to 6 weeks.
- Mice were injected with agitated BoNT-A at various time points to assess efficacy.
Main Results:
- A significant percentage of mice (50%) died within 48 hours after injection, indicating the toxin's potency was maintained.
- The efficacy of onabotulinumtoxinA persisted even after prolonged and vigorous agitation.
Conclusions:
- The neurotoxic effect of botulinum toxin type A is not significantly compromised by vigorous agitation for up to 6 weeks.
- Findings suggest that current handling precautions for reconstituted BoNT-A may be overly conservative.
Related Concept Videos
Botulism
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Tetanus
Bacterial Toxins
Diphtheria
Depolarizing Blockers: Pharmocokinetics

